|Swedish Orphan Biovitrum AB -- USA Stock|| |
USD 17.40 0.00 0.00%
Senior Vice President Manufacturing Operations
Ms. Kirsti Gjellan serves as Senior Vice President, Head of Biologics Development Supply at Swedish Orphan Biovitrum AB . She joined the Company in 2014. She is Pharmacist and holds a Doctorate of Philosophy degree in Pharmaceutical Technology from Universitetet i Oslo. Previously she was Factory Director, Biologics Manufacturing, MD at Pfizer Health AB and Board Member of Pfizer Health AB . She was also Director of Quality Operations, Pfizer . She has 17 years of experience from senior positions in research and manufacturing medicines at Astra Zeneca. She is also Board member of Processindustriell IT and Automation .
46 86 97 20 00 http://www.sobi.com
The company has return on total asset (ROA)
of 6.58 %
which means that it generated profit of $6.58 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 14.88 %
meaning that it generated $14.88 on every $100 dollars invested by stockholders.
The company has accumulated 64.15 M in total debt with debt to equity ratio (D/E) of 7.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Swedish Orphan Biovitrum AB has Current Ratio of 1.78 which is within standard range for the sector.
Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.